TaiGen Biopharmaceuticals Holdings (ROCO:4157) EBIT: NT$59.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4157 TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
59 GF Score
Price NT$8.90
GF Value NT$34.16
Valuation Significantly Undervalued
View Full Analysis

What is TaiGen Biopharmaceuticals Holdings EBIT?

TaiGen Biopharmaceuticals Holdings ROCO:4157 +0.34% 59 EBIT is NT$59.1 Mil as of Dec. 2025. GuruFocus rates ROCO:4157 with a GF Score™ of 59/100 and a GF Value™ of NT$34.16 (Significantly Undervalued).

TaiGen Biopharmaceuticals Holdings's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$217.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$59.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TaiGen Biopharmaceuticals Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was 628.67%. TaiGen Biopharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1,288.63%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TaiGen Biopharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.11%.

TaiGen Biopharmaceuticals Holdings  (ROCO:4157) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TaiGen Biopharmaceuticals Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=750.736 * ( 1 - 5.6% )/( (121.85 + 103.61)/ 2 )
=708.694784/112.73
=628.67 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1013.382 - 35.114 - ( 872.403 - max(0, 87.52 - 943.938+872.403))
=121.85

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1167.254 - 36.892 - ( 1026.752 - max(0, 83.105 - 1119.941+1026.752))
=103.61

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

TaiGen Biopharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=868.52/( ( (48.082 + max(26.653, 0)) + (17.314 + max(42.748, 0)) )/ 2 )
=868.52/( ( 74.735 + 60.062 )/ 2 )
=868.52/67.3985
=1,288.63 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.748 + 53.47 + 5.3639999999999) - (35.114 + 0 + 0.815)
=26.653

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.006 + 76.1 + 4.152) - (36.892 + 0 + 5.618)
=42.748

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TaiGen Biopharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=59.106/5336.433
=1.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiGen Biopharmaceuticals Holdings EBIT Related Terms

TaiGen Biopharmaceuticals Holdings EBIT Historical Data

* Premium members only.

The historical data trend for TaiGen Biopharmaceuticals Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiGen Biopharmaceuticals Holdings EBIT Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 876.24 -228.91 144.62 -31.46 59.11

TaiGen Biopharmaceuticals Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.22 -22.32 -122.17 -13.54 217.13

ROCO:4157 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TaiGen Biopharmaceuticals Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's EV-to-EBIT falls into.


ROCO:4157
59GF Score
TaiGen Biopharmaceuticals Holdings Ltd ROCO:4157
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiGen Biopharmaceuticals Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$59.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$59.1 Mil mean?
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a EBIT of NT$59.1 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TaiGen Biopharmaceuticals Holdings.
Is TaiGen Biopharmaceuticals Holdings' EBIT too high?
TaiGen Biopharmaceuticals Holdings' current EBIT is NT$59.1 Mil. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' EBIT compare to VRTX and REGN?
TaiGen Biopharmaceuticals Holdings' EBIT of NT$59.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TaiGen Biopharmaceuticals Holdings. TaiGen Biopharmaceuticals Holdings's current EBIT is NT$59.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.16, compared to a current price of NT$8.90 — trading 73.9% below its estimated fair value. The current EBIT is NT$59.1 Mil. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current EBIT is NT$59.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?

Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued. The current stock price of NT$8.90 is trading 73.9% below its estimated GF Value™ of NT$34.16. GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.

Key valuation signals for ROCO:4157:

  • EBIT: NT$59.1 Mil
  • GF Value™: NT$34.16 vs. price of NT$8.90 (73.9% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiGen Biopharmaceuticals Holdings Business Description

Address No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score

Get the complete analysis for ROCO:4157

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$8.90
Price
NT$34.16
GF Value